These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: B-cell activating factor promoter polymorphisms in egyptian patients with systemic lupus erythematosus.
    Author: Zayed RA, Sheba HF, Abo Elazaem MA, Elsaadany ZA, Elmessery LO, Mahmoud JA, Abdel Rahman DR, Abdou FR.
    Journal: Ann Clin Lab Sci; 2013; 43(3):289-94. PubMed ID: 23884224.
    Abstract:
    BACKGROUND: Systemic lupus erythematosus (SLE) is a heterogonous autoimmune disease involving most immune cells. Studies have revealed a number of cytokine pathways that play important roles in the disease process. Among these is B- cell activating factor (BAFF), which regulates B-cell maturation, survival, and function. OBJECTIVE: To study the association between BAFF promoter polymorphism and systemic lupus erythematosus (SLE). METHODS: Single nucleotide polymorphisms in the BAFF promoter region; -2841 (T>C), -2701 (T>A), -871 (C>T) were investigated by PCR-RFLP genotyping in fifty Egyptian SLE patients and thirty normal controls. RESULTS: The frequency of mutant alleles of both -871C>T and -2701 T>A was higher among SLE patients than controls (p-value <0.001 and 0.000 respectively). There was a highly significant relationship between -871 C>T polymorphism and SLE (P<0.001), with the sensitivity and the specificity of the test being 100 %, and 70%, respectively. Patients expressing the -2701 T>A allele were seven times more prone to SLE than those with the T/T wild genotype (sensitivity of the test = 78%, specificity = 66.7%, odds ratio = 7.09, C.I at 95% = 2.29-22.64). CONCLUSION: Polymorphisms in the regulatory region of the BAFF gene do contribute to the susceptibility to SLE in Egyptian patients, which indicates BAFF as a potential therapeutic target.
    [Abstract] [Full Text] [Related] [New Search]